Drug Profile
CP 2
Alternative Names: CP-2Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator AfaSci
- Developer AfaSci; Kansas State University; University of California, Davis
- Class Antidementias; Pyrones; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease; Diabetes mellitus
Highest Development Phases
- No development reported Alzheimer's disease; Diabetes mellitus
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (PO)
- 22 Jul 2016 CP 2 is available for licensing as of 22 Jul 2016. http://www.afasci.com/index.php/